Experimental drug INCB059872 tested in Tough-to-Treat sarcoma
NCT ID NCT03514407
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This early-phase trial tested the safety of a drug called INCB059872 in 25 people with Ewing sarcoma that had returned or stopped responding to standard treatments. The study aimed to see if the drug was safe and whether it could shrink tumors. However, the trial was terminated early, so full results are not available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED EWING SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Hospital Clínico San Carlos
Madrid, 28040, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Istituto Ortopedico Rizzoli
Bologna, 40136, Italy
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic Jacksonville - PPDS
Jacksonville, Florida, 32224, United States
-
Ospedale Pediatrico Bambino Gesu IRCCS
Rome, 00146, Italy
-
Policlinico Sant'orsola-Malpighi
Bologna, 40138, Italy
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
UCLA Jonsson Comprehensive Cancer
Los Angeles, California, 90095, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INCB059872
What this could lead to
If it works, this could point toward a new treatment option for people with Ewing sarcoma that has come back or not responded to standard therapy.
What could go wrong
This is a very early (Phase 1) study focused on safety, not yet proven to work. The trial was terminated, so results may be limited or inconclusive.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.